The life science market in 2026 combines cautious optimism with technological transformation: projected annual growth of 10.28% from 2026 to 2034, a global market reaching $269 billion by 2034, and a U.S. CAGR of 10–12%, set against regulatory uncertainty, funding fluctuations, slowed biotech IPO activity, and rising vacancy in biotech real estate hubs. This ETS fact sheet condenses the market picture into three pages.
It covers the drivers (aging populations, disease prevalence, AI-driven drug discovery, personalized therapies), the strategic response of major players through portfolio streamlining and M&A, North America's continued lead with Asia-Pacific as the fastest-growing region, and the workforce and venture-capital picture. It then shows how SAP answers the 2026 supply chain challenges: document management, audit trails, and QMS for FDA and EMA compliance, advanced demand planning and S&OP, end-to-end visibility with SAP ERP Cloud and IBP, batch and lot tracking, IoT and AI integration, security-by-design, and SuccessFactors for talent.
The full fact sheet is available above as a PDF. See also the "2026 Life Science Market Overview: Executive Brief" and the full "2026 Life Science Market Overview" deck in the Resource Library.